Aurobindo Pharma
Drug Manufacturers - Specialty & Generic · AUROPHARMA
Large CapHealthcareMature Stable
K. Nithyananda Reddy
Vice Chairman and Managing Director · Autocratic
Company DNA
Founder-Centric
About
Aurobindo Pharma is a Large Cap company in the Healthcare sector, listed on NSE as AUROPHARMA. With a market cap of ₹72K Cr and revenue of ₹31K Cr, it is currently in the Mature Stable phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Strong promoter involvement and control by the founding family, significantly influencing high-level business strategy. Its strategic mandate: To pivot from commoditized generics to high-margin specialty drugs, the firm needs leadership focused on R&D and portfolio diversification.
FAQ
What kind of company is Aurobindo Pharma?
Aurobindo Pharma is a Large Cap Healthcare company (AUROPHARMA) in the Mature Stable phase with a market cap of ₹72K Cr. It is classified as Founder-Centric in culture.
What is Aurobindo Pharma's culture and work environment like?
Aurobindo Pharma has a Founder-Centric culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Strong promoter involvement and control by the founding family, significantly influencing high-level business strategy.
Who leads Aurobindo Pharma?
Aurobindo Pharma is led by K. Nithyananda Reddy (Vice Chairman and Managing Director), a Autocratic leader with 39 years of experience.
What are Aurobindo Pharma's financials?
Aurobindo Pharma reported revenue of ₹31K Cr in FY25 with a 5-year revenue CAGR of 10.3%. Operating margin: 16.1%. Market cap: ₹72K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandValue-Champion
LifecycleMature Stable
Strong promoter involvement and control by the founding family, significantly influencing high-level business strategy.
Mandate
To pivot from commoditized generics to high-margin specialty drugs, the firm needs leadership focused on R&D and portfolio diversification.
To pivot from commoditized generics to high-margin specialty drugs, the firm needs leadership focused on R&D and portfolio diversification.
Financials
Revenue FY25₹31K Cr
PAT FY25₹3K Cr
Rev CAGR 5Y10.3%
OPM16.1%
NPM11.1%
ROE10.7%
ROCE14.4%
P/E21.6
Fwd P/E17.3
P/B2.1
D/E22.2
Mkt Cap₹72K Cr
Promoter54.2%
Institutional28.8%
Similar Culture
Could You Lead Aurobindo Pharma?
Take the Genome Benchmark →